-
Revenue: US$34.3m (up 38% from 3Q 2023).
-
Net income: US$8.35m (up from US$1.46m loss in 3Q 2023).
-
Profit margin: 24% (up from net loss in 3Q 2023).
-
EPS: US$0.02 (up from US$0.004 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates.
Looking ahead, revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada.
Performance of the Canadian Pharmaceuticals industry.
The company’s shares are up 2.1% from a week ago.
Just as investors must consider earnings, it is also important to take into account the strength of a company’s balance sheet. We have a graphic representation of Cronos Group’s balance sheet and an in-depth analysis of the company’s financial position.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Add Comment